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Background: Previous studies showed that desmopressin
decreases post-operative blood loss in patients undergoing cardiac
surgery. These studies were small and never studied the effect of
desmopressin in patients with active bleeding. Objective of the
study was to determine whether desmopressin reduces red blood
cells transfusion requirements in patients with active bleeding after
cardiac surgery who had been pre-treated with tranexamic acid.
Methods: This multicenter, randomized, double-blind, placebo-
controlled, parallel-group study randomized elective patients with
bleeding after cardiac surgery despite pre-treatment with tranex-
amic acid, to receive placebo (saline solution) or a single adminis-
tration of desmopressin (0.3 lg/kg in saline solution). The
primary endpoint was the number of patients requiring red blood
cells transfusion after randomization and during hospital stay.
Secondary end points were: blood loss from chest tubes during
the first 24 h after study drug administration, hours of mechanical
ventilation, intensive care unit stay, and in-hospital mortality.
Results: The study was interrupted after inclusion of 67% of the
planned patients for futility. The number of patients requiring red
blood cells transfusion after randomization was 37/68 (54%) in desmo-
pressin group and 33/67 (49%) in placebo group (P = 0.34) with no
difference in blood loss: 575 (interquartile 422–770) ml in desmo-
pressin group and 590 (476–1013) ml in placebo group (P = 0.42),
mechanical ventilation, intensive care unit stay or mortality.
Conclusions: This multicenter randomized trial demonstrated
that, in patients pre-treated with tranexamic acid, desmopressin
should not be expected to improve treatment of patients who
experience bleeding after cardiac surgery.
Editorial comment
Desmopressin is sometimes administered to perioperative patients in the hope of reducing periop-
erative bleeding. The findings from this clinical trial indicate that in patients treated with tranex-
amic acid before cardiac surgery who then have perioperative bleeding, the addition of
desmopressin treatment probably will not reduce bleeding.
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Peri-operative bleeding and the need for blood
transfusions are correlated with increased mor-
bidity, mortality, and costs.1–4 In cardiac sur-
gery, patients often require transfusions of
blood products and a surgical cause cannot be
identified in many patients. Among non-surgical
factors, hemostatic abnormalities are of para-
mount importance.
Pharmacological options to control peri-opera-
tive bleeding consist of topical agents, antifibri-
nolytic drugs, and drugs that improve primary
and/or secondary hemostasis. Among the latter
drugs, desmopressin (1-deamino-8-D-arginine
vasopressin, DDAVP) has been extensively
studied in several types of surgical interven-
tion,5 but mostly in patients undergoing cardiac
surgery with extracorporeal circulation.6,7
Desmopressin stimulate increases in plasma
concentrations of factor VIII and von Willebrand
factor and exerts other, less well-characterized
pro-hemostatic effects.8–10
Several randomized controlled trials
(RCTs)11,12 and a meta-analysis of RCTs5 sug-
gested that prophylactic desmopressin reduces
bleeding in surgical patients with a clinical
effect of approximately 3–4 h.13 Existing guide-
lines agree with the potential hemostatic proper-
ties of desmopressin, but do not give strong
recommendations.14,15 Notably, all the RCTs
performed so far have a small sample size, none
of them included patients with active post-
operative bleeding, and only one of them was
multicenter.
With the hypothesis that desmopressin might
reduce the transfusion rate of red blood cells
(RBC) in patients with excessive bleeding after
cardiac surgery, we performed a multicenter
RCT comparing a single dose infusion of desmo-
pressin vs. placebo. We also investigated in-hos-
pital mortality, blood loss/24 h, hours of
mechanical ventilation, duration of intensive
care unit, and hospital stay.
Methods
We performed a multicenter, randomized, dou-
ble-blind, placebo-controlled, parallel-group
trial to determine if desmopressin could reduce
the need for packed RBC transfusion after car-
diac surgery in patients with excessive bleeding
in the operating room or in the cardiac
post-operative intensive care unit (ICU). The
drug desmopressin is used in a way that is dif-
ferent from that described in the Food and Drug
Administration-approved drug label (‘off-label’
use).
Three teaching centers participated to the
study, all in Italy: IRCCS San Raffaele Scientific
Institute, Milan; IRCCS Policlinico San Donato,
Milan; and University Hospital of Pisa, Pisa.
The study was conceived in accordance with
the Declaration of Helsinki and its amendments.
The study protocol was approved by the Ethical
Committees of the three teaching centers
involved (Coordinating Center: Ospedale San
Raffaele Ethical Committee, IRCCS San Raffaele
Scientific Institute, via Olgettina 60, 20132
Milan; protocol n. DS/URC/ER/mm 151/DG;
date of approval: March 13th, 2006), registered
on ClinicalTrials.gov with the identifier
NCT00337766 and the first patient was random-
ized on June 2006.
All patients aged 18 years or more undergoing
elective cardiac surgery were asked to sign the
informed consent before surgery and if they met
the inclusion criteria they were randomized to
receive either desmopressin or placebo, in the
operating room or in the post-operative cardiac
ICU.
Inclusion/exclusion criteria 4
The inclusion criterion in the operating room
was diffuse bleeding without an identifiable
surgical source from the surgical site ≥ 15 min
after correct antagonization of heparin with pro-
tamine,12 likely to require management with
transfusion of platelets concentrates, fresh frozen
plasma, and/or RBC. This was decided jointly
by surgeons and anesthesiologists. The inclu-
sion criterion in the ICU was excessive bleeding
from chest tubes defined as 200 ml/h in 30 min
or 2 ml/kg/h for at least 2 h.16 Exclusion criteria
were lack of informed consent, and recent
(< 7 days) or ongoing acute myocardial infarc-
tion.
Randomization and experimental procedure
A computer-generated randomization sequence
stratified by center with blocks of 20 was used.
Acta Anaesthesiologica Scandinavica (2016)
2 ª 2016 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd
E. BIGNAMI ET AL.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
Treatment allocation (1 : 1) prepared by an
independent operator not otherwise involved in
the trial was concealed by opaque, sealed envel-
opes that were sequentially numbered. Patients,
managing physicians, and nurses were blinded
to treatment assignment for the whole duration
of the study. Desmopressin and placebo were
prepared in a separate room, as colorless fluids
in unlabeled bottles, by personnel who was not
involved in patients’ management and data col-
lection. Desmopressin (Kedrion, Barga, Lucca,
Italy) or an equivolume saline solution was
administered intravenously over 20 min at a
dose of 0.3 lg/kg diluted in a 50 ml saline solu-
tion. This dose was chosen because it was the
most frequently used (35 out of 41) in previous
RCTs performed in the peri-operative period.5
Registration of blood loss was started after com-
pleting study drug administration. Data were
collected by trained personnel who did not par-
ticipate in patients’ management and was
blinded to the assigned treatment. No protocol
violations were noted.
Clinical management
Enrolled patients were managed according to
standardized institutional practice for cardiac
surgery. This was a pragmatic trial and all
patients received the standard treatment accord-
ing to the anesthesiologist and the physician in
charge of the ICU. In patients on treatment with
double antiplatelet therapy, aspirin was main-
tained throughout the surgical procedure, while
drugs inhibiting the platelet P2Y12 receptor
were discontinued at least 5 days before sur-
gery. Patient monitoring included invasive
radial artery blood pressure measurement, con-
tinuous electrocardiographic leads II and V5
monitoring with ST-segment monitoring, pulse
oximetry, central venous pressure, capnometry,
urine output and trans-esophageal echocardiog-
raphy. All patients received an intravenous slow
bolus of 1 g tranexamic acid before surgery,
which was followed by a continuous infusion of
400 mg/h during the surgical intervention in
one institution (San Raffaele Scientific Insti-
tute), or by a second intravenous 1 g bolus after
the administration of protamine in the remain-
ing two institutions. A further dose of 500 mg
tranexamic acid was allowed after cardio
pulmonary bypass (CPB). Aprotinin was never
administered.
CPB management
Surgery was conducted either with CPB or off
pump. Cardio pulmonary bypass was conducted
mostly at moderate hypothermia (32–34°C). In
CPB procedures, myocardial protection during
aortic cross-clamping was obtained by antegrade
and/or retrograde cold blood cardioplegia or
antegrade crystalloid cardioplegia according to
the local standard. Heparin was administered as
intravenous bolus of 300 IU/kg to patients under-
going CPB, or 150 IU/kg to patients undergoing
off pump procedures. Activated clotting time was
maintained longer than 480 s during CPB and
longer than 300 s during off pump procedures.
Upon achievement of normothermia, extracorpo-
real circulation was discontinued and heparin
was neutralized with protamine sulfate (1 mg per
100 IU heparin).
Intensive care management
Patients were transferred to the ICU, sedated
with propofol 2 mg/kg/h for 4 h, and weaned
from the ventilator as soon as they were hemo-
dynamically stable with no major bleeding, nor-
mothermic, and achieved an adequate level of
consciousness and analgesia. Intravenous mor-
phine was administered to all patients for post-
operative pain relief. In case of bleeding, the
surgeon was summoned to decide if surgical
revision was suitable. Criteria for ICU discharge
to post-intensive cardiac surgery ward were res-
piratory and hemodynamic stability and no
active bleeding from chest tubes.
Bleeding and transfusion management
The amount of blood loss from chest tubes was
recorded hourly for 48 h after surgery or until
chest tubes removal, whichever came first. The
number of transfused platelet concentrates, fresh
frozen plasma, and RBC were recorded. Transfu-
sions were administered following a pre-
defined protocol: if hemoglobin was < 8 g/dl,
one RBC was transfused. In case of bleeding
from chest tubes, if prothrombin time (INR)
was ≤ 1.39, no fresh frozen plasma was infused,
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if platelets count was > 100 9 109/l, no platelets
concentrates were infused. In the operating
room, advanced patient’s age or hemodynamic
instability were factors that allowed a lower
threshold for RBC transfusion, according to the
attending anesthesiologist.
Data collection
We collected data on need of re-thoracotomy
due to excessive bleeding, length of mechanical
ventilation and of ICU stay. All randomized
patients were followed up till hospital dis-
charge.
Laboratory-based hematological tests, includ-
ing complete blood cells count, prothrombin
time ratio, PTT ratio, and biochemistry tests,
including serum creatinine, troponin I, transam-
inase, and plasma sodium concentration were
done before and after surgery, on arrival in ICU
and on the first post-operative day. The antico-
agulant effect of heparin was monitored by kao-
lin-activated clotting time before and after CPB.
Endpoints
The pre-specified main outcome measure was
the number of patients requiring RBC transfu-
sion after randomization and during hospital
stay. Secondary end points were: blood loss
from chest tubes during the first 24 h after study
drug administration, hours of mechanical venti-
lation, ICU stay, and in-hospital mortality.
Sample size calculation
On the basis of previous data17,18 investigating
post-operative RBC transfusion in patients at
high risk of bleeding after cardiac surgery and
on our experience, we anticipated a 65% fre-
quency of transfusion of RBC in the standard
treatment group and a reduction to 45% after
treatment with desmopressin (we tested the
hypothesis that desmopressin administration
would reduce the need of RBC transfusion
when compared to placebo with an absolute
risk reduction of 20% and a relative risk reduc-
tion of 30%). Sample size calculations, based on
a two-sided alpha error of 0.05 and 80% power,
indicated that a sample size of 100 patients per
group was necessary.
Ad interim analysis and study interruption
We experienced a low enrollment rate due to
organizing problems and lack of funding and
we decided to perform an unplanned ad interim
analysis after enrolling 67% of the patients. As
showed in supplemental material
(Appendix S1, Figs S1 and S2) the trial was
considered to have reached its goal of testing
the null hypothesis with adequate statistical
precision and was stopped for futility.
Statistical analyses
All data were analyzed according to the inten-
tion-to-treat principle. Data were stored elec-
tronically and analyzed by use of SAS software,
version 9 (SAS Institute 5). All data analysis was
carried out according to a pre-established analy-
sis plan and results are presented as mean  s-
tandard deviation, median (interquartile range),
or number (percentage). Dichotomous data were
compared using two-tailed Chi-square test with
the Yates correction or Fisher’s exact test when
appropriate; 95% confidence interval estimation
for the differences between independent propor-
tions was performed with methods based on the
Wilson score. Continuous measures were com-
pared by analysis of variance (ANOVA) or the
Mann–Whitney U-test when appropriate; 95%
confidence interval estimate for the mean/me-
dian difference was performed. Two-sided sig-
nificance tests were used throughout our data
analysis.
Results
During the study period, 3552 patients signed
the written informed consent. A total of 135
(3.8%) patients had excessive bleeding after car-
diac surgery and were randomized to desmo-
pressin (n = 68) or placebo (n = 67) (Fig. 1).
The study was interrupted for futility at an ad
interim analysis performed after enrolling 67%
of the planned patients. All 135 included
patients completed their hospital follow-up.
The two groups of patients had similar charac-
teristics at baseline (Table 1). Mean age was
63 years, 100 (74%) were males and 54 (40%)
were on treatment with antiplatelet drugs.
Seventy-three patients (54%) were randomized
Acta Anaesthesiologica Scandinavica (2016)
4 ª 2016 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd
E. BIGNAMI ET AL.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
in the operating theater and 62 (46%) in the
ICU after a median of 120 (60–180) min after
arrival to ICU.
All patients received a single intravenous
administration of placebo or desmopressin
0.3 lg/kg, without protocol deviations.
The number of patients receiving RBC trans-
fusions after randomization was similar in the
desmopressin (37/68, 54%) and in the placebo
group (33/67, 49%) (P = 0.34) (Table 2).
No statistically significant differences were
observed between the two treatment groups in
terms of hours of mechanical ventilation, days
in ICU and other outcomes (Table 2). Five
patients (7.4%) in the desmopressin group and
4 (6.0%) in the placebo group died (P = 0.99).
Neither differences in bleeding nor RBC trans-
fusion was observed in subanalyses of patients
randomized in the theater (Table S1) and those
randomized in the ICU (Table S2).
Discussion
In this multicenter, double-blind, placebo-con-
trolled RCT, we found that desmopressin was
not effective in reducing post-operative blood
loss and RBC transfusion requirements in
patients undergoing cardiac surgery who experi-
enced excessive bleeding after successful hep-
arin neutralization despite pre-treatment with
tranexamic acid. Moreover, no statistically sig-
nificant differences in mortality rates or in any
other outcomes were observed, even if the
power for these analyses was low. Transfusion
of RBC did not differ significantly also in pre-
defined subgroups. The study was interrupted
for futility after enrolling 67% of the planned
patients.
Previous studies evaluating the blood saving
effects of desmopressin in patients undergoing
cardiac surgery gave conflicting results. A meta-
analysis of 17 studies17 showed that desmo-
pressin decreased post-operative blood loss by
34% in those trials in which the 24 h blood loss
in the placebo-treated patients was in the upper
third of distribution, suggesting that the drug
may be clinically efficacious only in patients at
risk of excessive post-operative bleeding.17 The
data of this meta-analysis were substantially
confirmed in a later prospective, double-blind,
placebo-controlled trial, in which the effects of
desmopressin were compared to those of pla-
cebo in patients identified as being at high risk
of post-operative bleeding with the point-of-care
Fig. 1. Assessment, randomization and
follow-up of study patients.
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test hemoSTATUS.12 The trial showed that the
average 24 h blood loss in desmopressin-trea-
ted, high-risk patients was 39% lower than that
in placebo-treated high-risk patients and was
comparable to that of low risk, untreated
patients. The most important difference between
our study and previous studies is that as part of
modern cardiac surgery19,20 we used tranexamic
acid in all patients included in the present trial.
Interestingly, 1000 ml of blood loss in the first
post-operative 24 h seems to be the cut-off value
that identifies patients who may potentially
benefit from this treatment.19 Therefore, we
speculate that, when an adequate prophylaxis
with antifibrinolytic agents is administered to
patients, excessive post-operative bleeding is
not severe enough to benefit from the pro-hemo-
static effect of desmopressin.
In a recent meta-analysis of 38 randomized pla-
cebo-controlled trials (2488 patients) in cardiac
and non-cardiac surgery, Crescenzi et al. showed
that desmopressin was associated with reduced
requirements of blood product transfusion [stan-
dardized mean difference = 0.29 (0.52 to
0.06) units per patient; P = 0.01], and with a
non-statistically significant increase in throm-
boembolic adverse events (57/1002 = 5.7% in the
desmopressin group vs. 45/979 = 4.6% in the
Table 1 Baseline characteristics according to randomized group assignment (desmopressin vs. placebo).
Variable Desmopressin (68 patients) Placebo (67 patients)
Age, years 64  13.3 62  13.2
No. of patients aged > 75 years 15 (23%) 13 (20%)
Women 18 (27%) 17 (25%)
Weight, kg 73  13.5 73  13.8
Height, cm 169  8.4 170  8.1
Cirrhosis, no. 2 (3%) 1 (1.5%)
On antiplatelet drugs, no. 25 (38%) 29 (43%)
Acetylsalicylic acid, no. 21 (31%) 16 (24%)
Ticlopidine, no. 4 (5.9%) 5 (7.5%)
Clopidogrel, no. 8 (12%) 9 (13%)
Tirofiban, no. 1 (1.5%) 1 (1.5%)
Congenital defect of primary hemostasis, no. 1 (1.5%) 1 (1.5%)
Activated clotting time before surgery, seconds 147  29.4 145  24.4
Activated clotting time at end of CPB, seconds 140  29.0 140  20.7
Hemoglobin preoperative, g/dl 13.3  1.85 13.4  1.89
Hematocrit preoperative, % 39.3  5.19 39.6  5.15
Platelet count preoperative, 9103/mm3 204  73.4 204  60.5
PT ratio preoperative 1.2  0.31 1.2  0.53
PTT ratio preoperative 1.1  0.25 1.2  0.39
Serum creatinine preoperative, mg/dl 0.90 (0.79–1.08) 0.96 (0.82–1.1)
No. of patients whit preoperative creatinine > 1.5 mg/dl 7 (11%) 5 (7.6%)
Randomization in the operating theater, no. 37 (54%) 36 (54%)
Minutes between CPB weaning and randomization in the theater 60 (30–80) 50 (40–79.8)
Randomization in the ICU, no. 31 (46%) 31 (46%)
Minutes between ICU admission and randomization in the ICU 120 (60–157.5) 145 (60–240)
Supplemental dose of tranexamic acid, no. 35 (52%) 34 (51%)
No. of patients transfused with any blood product before randomization 31 (46%) 34 (51%)
No. of patients transfused with RBC before randomization 24 (35%) 28 (42%)
No. of RBC units transfused/patient before randomization 2 (1.75–3) 2 (1–3)
No. of patients transfused with FFP pre-randomization 20 (29%) 21 (31%)
No. of FFP units transfused/patient before randomization 2 (1.75–3.25) 2 (2–3)
No. of patients transfused with PLT pre-randomization 10 (15%) 9 (13%)
No. of PLT units transfused/patient before randomization 1 (1–1) 1 (1–1)
No., number; CPB, cardiopulmonary bypass; PT, prothrombin time; INR, international normalized ratio; PTT, partial thromboplastin time; Na,
sodium; ICU, intensive care unit; RBC, red blood cell; FFP, fresh frozen plasma; PLT, platelets.
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placebo group; P = 0.3).6 Our study will also
help to modify the message of the existing guide-
lines14,15 for the peri-operative management of
desmopressin. At the moment, they are both sug-
gesting potential benefits in reducing blood loss
in the presence of coagulopathy conditions, but
they are based on small single-center trials or
meta-analysis21 performed in settings that did
not routinely use tranexamic acid. In this
multicenter randomized trial desmopressin did
not translate into a reduced rate of patients
requiring RBC transfusion among those with
active bleeding after cardiac surgery who had
been pre-treated with tranexamic acid.
Importantly, it is necessary to investigate
further how to improve outcomes of patients
with bleeding after surgery, which has a high
mortality rate, as confirmed by the results of our
Table 2 Post-randomization data according to randomized group assignment (desmopressin vs. placebo).
Variable Desmopressin (68 patients) Placebo (67 patients) P value
No. of patients transfused with RBC post-randomization 37 (54%) 33 (49%) 0.34
No. of RBC units transfused/patient post-randomization 2 (1–4) 2 (1–3) 0.74
No. of patients transfused with FFP post-randomization 24 (35%) 25 (37%) 0.62
No. of FFP units transfused/patient post-randomization 2.5 (2–4) 3 (2–3) 0.77
No. of patients transfused with PLT post-randomization 9 (13%) 10 (15%) 0.62
No. of PLT units transfused/patient post-randomization 1 (1–3) 1 (1–2) 0.90
No. of patients transfused with any blood product post-randomization 40 (59%) 35 (52%) 0.44
Chest tube blood loss in the first 12 h after study drug administration, ml 400 (267.5–700) 430 (325–800) 0.34
Chest tube blood loss in the first 24 h after study drug administration, ml 575 (422.5–770) 590 (476.25–1013.75) 0.42
Bleeding at drainage removal, ml 850 (600–1390) 1040 (565–1457.5) 0.69
Hemoglobin at ICU admission, g/dl 11.1  1.74 11.1  1.68 0.67
Hemoglobin in the 1st morning, g/dl 10.8  1.36 11.1  1.46 0.16
Hemoglobin in the 2nd morning, g/dl 10.6  1.41 10.7  1.23 0.78
Hematocrit at ICU admission, % 33.1  4.70 33.1  4.83 0.98
Hematocrit in the 1st morning, % 31.8  4.08 32.7  4.04 0.23
Hematocrit in the 2nd morning, % 31.0  4.14 31.3  3.90 0.68
Platelet count at ICU admission, 9103/mm3 136  69.8 128  47.6 0.47
Platelet count in the 1st morning, 9103/mm3 136  62.4 140  58.0 0.74
Platelet count in the 2nd morning, 9103/mm3 135  68.1 128  55.0 0.63
PT ratio at ICU admission 1.4  0.32 1.4  0.28 0.65
PT ratio in the 1st morning 1.3  0.21 1.2  0.18 0.61
PT ratio in the 2nd morning 1.4  0.48 1.3  0.25 0.94
PTT ratio at ICU admission 1.1  0.27 1.2  0.34 0.85
PTT ratio in the 1st morning 1.1  0.12 1.0  0.10 0.85
PTT ratio in the 2nd morning 1.1  0.19 1.1  0.15 0.66
Serum creatinine at ICU admission, mg/dl 0.97 (0.82–1.09) 0.89 (0.75–1.09) 0.23
Serum creatinine in the 1st morning, mg/dl 1.15 (0.95–1.4) 1.22 (0.89–1.56) 0.94
Serum creatinine peak level in the ICU, mg/dl 1.23 (1.02–1.71) 1.14 (0.95–1.57) 0.37
Serum troponin I at ICU admission, ng/l 4.1 (2.1–8.4) 5.1 (2.1–8.9) 0.73
Serum troponin I in the 1st morning, ng/l 6.8 (2.6–11.3) 5.8 (3.3–11.1) 0.97
Serum troponin I peak level, ng/l 8.4 (3.4–11.5) 7.5 (3.9–13.6) 0.70
Hypotension during study drug administration, no. 12 (18%) 4 (6.0%) 0.11
Hypotension requiring intervention, no. 3 (4.4%) 2 (3.0%) 0.90
Surgical revision, no. 8 (12%) 12 (18%) 0.39
Surgical source of bleeding in re-operated patients, no. 5/8 (62%) 5/12 (42%) 0.36
Mechanical ventilation, h 17 (11–34) 16 (10.75–31) 0.92
ICU stay, days 2 (1–4) 2 (1–4) 0.63
Thrombosis, no. 3 (4.4%) 2 (3.0%) 0.51
Hospital mortality, no. 5 (7.4%) 4 (6.0%) 0.99
No., number; ICU, intensive care unit; RBC, red blood cell; FFP, fresh frozen plasma; PLT, platelets; PT, prothrombin time; INR, international nor-
malized ratio; PTT, partial thromboplastin time.
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study: 6.7% in the patients included in this
study vs. 2.2–3.4% published22,23 mortality
reported in the overall population undergoing
cardiac surgery in our centers.
This trial was randomized and double-
blinded in design with allocation concealment,
thus reducing the risk of selection bias. It
focused on patient-centered, objectively verifi-
able and clinically relevant outcomes, thus
reducing ascertainment bias. The intervention
had biological plausibility and was supported
by a series of single-center studies with promis-
ing results and by meta-analyses, thus justifying
the initial trial hypothesis. Our results likely
carry external validity because patients were
recruited in three different hospitals with the
use of pragmatic inclusion criteria and few
exclusion criteria. They are also likely to be
highly reproducible, as the trial protocol was
simple, with routine practice maintained
throughout, except for desmopressin or placebo
infusion.
A limitation of our study is that it was inter-
rupted prematurely, after the enrollment of 135
of the planned 200 patients; even if this caused
a reduction in power, the case for the futility of
the intervention was clear. Despite its premature
interruption, this is the largest multicenter RCT
ever performed with desmopressin as a hemo-
static agent in the peri-operative period and one
of the few to study patients who were actively
bleeding. This was a pragmatic trial and we did
not change the routine of our centers to perform
the protocol; at the same time we acknowledge
that we did not collect some important data that
could influence coagulability such as kind of
surgery (e.g., off pump CABG); CPB duration,
pH, calcium, and the number of patients oper-
ated under hypothermia or with normothermia.
A possible limitation of our study is that the
inclusion criteria in the theater might be consid-
ered less objective and relevant that the inclu-
sion criteria in the ICU, but hemostasis is
optimized in the operating rooms and other
investigators randomized patients in this setting.
Furthermore, results in the two groups (theater
and ICU) were similar.
In conclusion, this multicenter randomized
trial demonstrated that in patients pre-treated
with tranexamic acid, desmopressin should not
be expected to improve treatment of patients
who experience bleeding after cardiac surgery.
Therefore, also considering its potential side
effects, the routine use of desmopressin as a
blood saving agent in this setting is not justi-
fied.
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